Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

54P - Real-world efficacy of immunotherapy plus anti-angiogenesis versus immunotherapy monotherapy as second-line or later treatment in advanced non-small cell lung cancer


31 Mar 2023


Poster Display session


Yao Zhang


Journal of Thoracic Oncology (2023) 18 (4S): S35-S88.


Y. Zhang1, H. Qiang2, H. Zhong2

Author affiliations

  • 1 Shanghai/CN
  • 2 Shanghai Chest Hospital , School of Medicine,Shanghai Jiao Tong University, 200030 - Shanghai/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 54P


Previous clinical research has demonstrated that immunotherapy plus anti-angiogenesis have a synergistic effect and achieved promising clinical outcomes in treating advanced NSCLC patients as first-line therapy. However, there are limited data for immunotherapy plus anti-angiogenesis as second-line or salvage therapy. Herein, we conduct a retrospective study to evaluate the efficacy of immunotherapy in combination with anti-angiogenesis as second-line or later therapy for patients with advanced NSCLC in the real world.


We retrospectively enrolled eligible patients with advanced NSCLC who were treated with immunotherapy plus anti-angiogenesis (I+A group) or immunotherapy monotherapy (IM group) as second-line or later therapy at Shanghai Chest Hospital from January 1, 2018, to March 30, 2022. The clinical information was collected, and the treatment outcomes and survival data were assessed and compared between the two groups.


A total of 211 patients were included in this study (83 patients in the I+A group and 128 patients in the IM group). The I+A group achieved a higher objective response rate (ORR) compared with the IM group (27.7% VS. 3.9%, P < 0.001). The median progression-free survival (PFS) was 6.77 months VS. 4.67 months (P < 0.001), and the median overall survival (OS) was 16.73 months VS. 12.63 months (P = 0.035), respectively. In the subgroup analysis, patients who received immunotherapy as second-line treatment were more likely to benefit from combination therapy (mPFS: 8.93months VS. 4.03 months, P < 0.001). Additionally, multivariate analysis showed that immunotherapy plus anti-angiogenesis had significantly prolonged the PFS and OS (P = 0.011 and P = 0.008).


Immunotherapy plus anti-angiogenesis achieved longer PFS and OS in patients with advanced NSCLC in the second-line or posterior treatment. Further prospective research should be conducted on larger populations.

Legal entity responsible for the study

The authors.


National Natural Science Foundation of China (No. 82072573, 82002426)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.